GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Daxor Corp (NAS:DXR) » Definitions » Piotroski F-Score

Daxor (DXR) Piotroski F-Score : 3 (As of Apr. 26, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Daxor Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Daxor has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Daxor's Piotroski F-Score or its related term are showing as below:

DXR' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 7
Current: 3

During the past 13 years, the highest Piotroski F-Score of Daxor was 7. The lowest was 2. And the median was 4.


Daxor Piotroski F-Score Historical Data

The historical data trend for Daxor's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daxor Piotroski F-Score Chart

Daxor Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 2.00 3.00 4.00 3.00

Daxor Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 - 4.00 - 3.00

Competitive Comparison of Daxor's Piotroski F-Score

For the Medical Instruments & Supplies subindustry, Daxor's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daxor's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Daxor's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Daxor's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was $0.28 Mil.
Cash Flow from Operations was $-3.66 Mil.
Revenue was $1.28 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was (30.261 + 34.869) / 2 = $32.565 Mil.
Total Assets at the begining of this year (Dec22) was $30.26 Mil.
Long-Term Debt & Capital Lease Obligation was $0.76 Mil.
Total Assets was $34.87 Mil.
Total Liabilities was $0.86 Mil.
Net Income was $5.18 Mil.

Revenue was $6.31 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was (24.982 + 30.261) / 2 = $27.6215 Mil.
Total Assets at the begining of last year (Dec21) was $24.98 Mil.
Long-Term Debt & Capital Lease Obligation was $1.23 Mil.
Total Assets was $30.26 Mil.
Total Liabilities was $1.29 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Daxor's current Net Income (TTM) was 0.28. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Daxor's current Cash Flow from Operations (TTM) was -3.66. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=0.281/30.261
=0.00928588

ROA (Last Year)=Net Income/Total Assets (Dec21)
=5.178/24.982
=0.20726923

Daxor's return on assets of this year was 0.00928588. Daxor's return on assets of last year was 0.20726923. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Daxor's current Net Income (TTM) was 0.28. Daxor's current Cash Flow from Operations (TTM) was -3.66. ==> -3.66 <= 0.28 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=0.756/32.565
=0.02321511

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=1.229/27.6215
=0.04449433

Daxor's gearing of this year was 0.02321511. Daxor's gearing of last year was 0.04449433. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

* Note that for banks and insurance companies, there's no Total Current Assets and Total Current Liabilities reported. Thus, we use Total Assets and Total Liabilities to calculate current ratio for banks and insurance companies.

Current Ratio (This Year: Dec23)=Total Assets/Total Liabilities
=34.869/0.859
=40.59254948

Current Ratio (Last Year: Dec22)=Total Assets/Total Liabilities
=30.261/1.292
=23.42182663

Daxor's current ratio of this year was 40.59254948. Daxor's current ratio of last year was 23.42182663. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Daxor's number of shares in issue this year was 4.631. Daxor's number of shares in issue last year was 4.084. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

* Note that for banks and insurance companies, there's no Gross Profit reported. Thus, we use net income instead of gross profit and calculate Net Margin for this score.

Net Margin (This Year: TTM)=Net Income/Revenue
=0.281/1.281
=0.21935988

Net Margin (Last Year: TTM)=Net Income/Revenue
=5.178/6.31
=0.82060222

Daxor's net margin of this year was 0.21935988. Daxor's net margin of last year was 0.82060222. ==> Last year's net margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=1.281/30.261
=0.04233171

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=6.31/24.982
=0.25258186

Daxor's asset turnover of this year was 0.04233171. Daxor's asset turnover of last year was 0.25258186. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+0+0+1+1+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Daxor has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Daxor  (NAS:DXR) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Daxor Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Daxor's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Daxor (DXR) Business Description

Traded in Other Exchanges
Address
109 Meco Lane, Oak Ridge, TN, USA, 37830
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. It develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
Executives
Robert J Michel officer: CHIEF FINANCIAL OFFICER C/O ASTA FUNDING, INC., 210 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Michael Richard Feldschuh director 71 GRAND STREET #2, NEW YORK NY 10013
Joy S. Goudie director 350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Caleb Desrosiers director DAXOR CORPORATION, 109 MECO LANE, OAK RIDGE TN 37830
Henry D. Cremisi director 350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Edward Feuer director 2 WALL STREET, 10TH FLOOR, NEW YORK NY 10005
Soren Thompson officer: V.P./BUSINESS DEVELOPMENT 180 CENTRAL PARK SOUTH, APT. 805, NEW YORK NY 10019
Jonathan Adam Feldschuh director, officer: CHIEF SCIENTIFIC OFFICER DAXOR CORPORATION, 350 5TH AVENUE, SUITE 4740, NEW YORK NY 10118
Joseph Feldschuh officer: President 615 W. 252ND STREET, BRONX NY 10471
Estate Of Joseph Feldschuh other: FOUNDER 350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Diane Marie Meegan officer: Corporate Secretary 259 NEW YORK AVENUE, JERSEY CITY NJ 07307
Bernhard Saxe director 6805 WILD ROSE COURT, SPRINGFIELD VA 25152
Robert Willens director 200 EAST 74TH ST APT 18C, NEW YORK NY 10021
Philip Nordan Hudson director P.O. BOX 160892, SAN ANTONIO TX 78280-3092
Everis Engstrom officer: Vice President 3244 BLACK FOX ROAD, WASHBURN TN 37888

Daxor (DXR) Headlines

From GuruFocus